Experimental Hepatitis C Drug Not Yet Accepted by FDA
Idenix says FDA delays hepatitis C drug trials
By The Associated Press
June 20, 2013
NEW YORK (AP) — Idenix Pharmaceuticals Inc. said Thursday the Food and Drug Administration wants more safety data on its experimental hepatitis C drug IDX20963 before it will allow the company to begin human testing.
Continue reading this entire article:
Hepatitis C Virus Survival: Syringe Specifics
New Hepatitis C Genotype Test Approved by the FDA